Terms: = Endocrine gland cancer AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130
60 results:
1. SK-Unet++: An improved Unet++ network with adaptive receptive fields for automatic segmentation of ultrasound thyroid nodule images.
Dai H; Xie W; Xia E
Med Phys; 2024 Mar; 51(3):1798-1811. PubMed ID: 37606374
[TBL] [Abstract] [Full Text] [Related]
2. Association between contralateral adrenal and hypothalamus-pituitary-adrenal axis in benign adrenocortical tumors.
Zhu H; Wu L; Su T; Jiang L; Zhou W; Jiang Y; Zhang C; Zhong X; Wang W
Front Endocrinol (Lausanne); 2023; 14():1199875. PubMed ID: 37560307
[TBL] [Abstract] [Full Text] [Related]
3. Butein Inhibits Cell Growth by Blocking the IL-6/IL-6Rα Interaction in Human Ovarian cancer and by Regulation of the IL-6/STAT3/FoxO3a Pathway.
Park SA; Seo YJ; Kim LK; Kim HJ; Yoon KD; Heo TH
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047012
[No Abstract] [Full Text] [Related]
4. gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144.
Pozios I; Hering NA; Guenzler E; Arndt M; Elezkurtaj S; Knösel T; Bruns CJ; Margonis GA; Beyer K; Seeliger H
J Cancer Res Clin Oncol; 2023 Jan; 149(1):271-280. PubMed ID: 36495330
[TBL] [Abstract] [Full Text] [Related]
5. Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer.
Suzuki H; Mitsunaga S; Ikeda M; Aoyama T; Yoshizawa K; Yamaguchi M; Suzuki M; Narita M; Kawasaki T; Ochiai A
Cancer Med; 2022 Dec; 11(24):5001-5012. PubMed ID: 35578571
[TBL] [Abstract] [Full Text] [Related]
6. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling.
Huo Y; Yang J; Zheng J; Xu D; Yang M; Tao L; Yao H; Fu X; Yang J; Liu D; Hua R; Zhang J; Sun Y; Hu L; Liu W
Cell Prolif; 2022 May; 55(5):e13237. PubMed ID: 35487760
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of gp130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract] [Full Text] [Related]
8. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
Peisl S; Mellenthin C; Vignot L; Gonelle-Gispert C; Bühler L; Egger B
PLoS One; 2021; 16(6):e0252397. PubMed ID: 34138876
[TBL] [Abstract] [Full Text] [Related]
10. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract] [Full Text] [Related]
11. Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis.
Aftabizadeh M; Li YJ; Zhao Q; Zhang C; Ambaye N; Song J; Nagao T; Lahtz C; Fakih M; Ann DK; Yu H; Herrmann A
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491667
[TBL] [Abstract] [Full Text] [Related]
12. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract] [Full Text] [Related]
13. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell cancer.
Azar WJ; Christie EL; Mitchell C; Liu DS; Au-Yeung G; Bowtell DDL
Cancer Res; 2020 Nov; 80(22):4960-4971. PubMed ID: 32917727
[TBL] [Abstract] [Full Text] [Related]
14. Enhanced recovery for obese patients undergoing gynecologic cancer surgery.
Harrison R; Iniesta MD; Pitcher B; Ramirez PT; Cain K; Siverand AM; Mena G; Lasala J; Meyer LA
Int J Gynecol Cancer; 2020 Oct; 30(10):1595-1602. PubMed ID: 32848023
[TBL] [Abstract] [Full Text] [Related]
15. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
[TBL] [Abstract] [Full Text] [Related]
16. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup.
Liu C; Deng S; Jin K; Gong Y; Cheng H; Fan Z; Qian Y; Huang Q; Ni Q; Luo G; Yu X
Int J Oncol; 2020 Apr; 56(4):900-908. PubMed ID: 32319567
[TBL] [Abstract] [Full Text] [Related]
17. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract] [Full Text] [Related]
18. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract] [Full Text] [Related]
19. Effect of preoperative computed tomography parameters and obesity on surgical outcomes of laparoendoscopic single-site adrenalectomy.
Chen YC; Lee HY; Shih MP; Juan YS; Chen HW; Wu WJ; Wang YT; Li CC
Surg Endosc; 2020 Nov; 34(11):4781-4787. PubMed ID: 31792689
[TBL] [Abstract] [Full Text] [Related]
20. Broadening horizons with
Ballal S; Yadav MP; Bal C; Sahoo RK; Tripathi M
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):934-946. PubMed ID: 31707430
[TBL] [Abstract] [Full Text] [Related]
[Next]
